SCHEMBL6042422

SCHEMBL6042422

CC(C)(C)[SiH2]OC(c1ccccc1)(c1ccccc1)C1CN(Cc2ccccc2)CCC1(O)c1ccc(Br)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
TSHR P16473 1/20 0.42
MEN1 O00255 1/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
MAPK1 P28482 1/20 0.42
KMT2A Q03164 1/20 0.42
OPRL1 P41146 1/20 0.37
CCR3 P51677 1/20 0.36
POLB P06746 1/20 0.36
BCHE P06276 2/20 0.36
ACHE P22303 2/20 0.36
BACE1 P56817 2/20 0.36
HPGD P15428 1/20 0.34
DUSP3 P51452 1/20 0.34
PTPN5 P54829 1/20 0.34
PTPN11 Q06124 1/20 0.34
CHRM2 P08172 2/20 0.34
CHRM3 P20309 2/20 0.34
CHRNA7 P36544 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6651907 0.92 ALDH1A1 (0.43) ALDH1A1TSHRMEN1LMNAMAPT
SCHEMBL16799739 0.75 ALDH1A1 (0.57) ALDH1A1TSHRMEN1LMNAMAPT
SCHEMBL6043574 0.72 ALDH1A1 (0.53) ALDH1A1TSHRMEN1LMNAMAPT
SCHEMBL6042627 0.72 ALDH1A1 (0.43) ALDH1A1MEN1KMT2AACHECHRM3
SCHEMBL6042419 0.70 ALDH1A1 (0.42) ALDH1A1TSHRMEN1LMNAMAPT
SCHEMBL6042415 0.70 ALDH1A1 (0.51) ALDH1A1TSHRMEN1LMNAMAPT
SCHEMBL6042725 0.69 TACR1 (0.49) MEN1KMT2A
SCHEMBL11558827 0.67 ALDH1A1 (0.67) ALDH1A1TSHRMEN1LMNAMAPT
SCHEMBL2591097 0.66 OPRL1 (0.79) ALDH1A1KMT2AOPRL1CCR3POLB
Hydrochloric Acid SCHEMBL3146791 0.65 POLB (0.80) ALDH1A1KMT2AOPRL1CCR3POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060079533-A1 Methods of treating alzheimer's disease NIEMAN JAMES A 2006-04-13 US disclosed
WO-2002076440-A2 METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES ELAN PHARMACEUTICALS, INC. (US) 2002-10-03 WO disclosed
US-6150526-A Piperidine derivative having renin inhibiting activity HOFFMANN-LA ROCHE INC. (US) 2000-11-21 US disclosed
US-6051712-A PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS HOFFMANN-LA ROCHE INC. (US) 2000-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079533-A1 Methods of treating alzheimer's disease BACE1, PSEN1, PSEN2 ALDH1A1 2504/4885TSHR 3417/4885MEN1 2561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.